Literature DB >> 20519186

[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].

Tatjána Abel1, János Fehér.   

Abstract

Type 2 diabetes is a very common worldwide disorder. A good glycemic control is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20519186     DOI： 10.1556/OH.2010.28910

Source DB:  PubMed          Journal:  Orv Hetil        ISSN： 0030-6002            Impact factor:   0.540


  3 in total

1.  Lycopene ameliorates renal function in rats with streptozotocin-induced diabetes.

Authors:  Wei Li; Guoguang Wang; Xiaohua Lu; Yuxin Jiang; Lei Xu; Xue Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

2.  Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

Authors:  Cristina Mega; Edite Teixeira de Lemos; Helena Vala; Rosa Fernandes; Jorge Oliveira; Filipa Mascarenhas-Melo; Frederico Teixeira; Flávio Reis
Journal:  Exp Diabetes Res       Date:  2011-11-30

Review 3.  Past and current perspective on new therapeutic targets for Type-II diabetes.

Authors:  Pradip D Patil; Umesh B Mahajan; Kalpesh R Patil; Sandip Chaudhari; Chandragouda R Patil; Yogeeta O Agrawal; Shreesh Ojha; Sameer N Goyal
Journal:  Drug Des Devel Ther       Date:  2017-05-22       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.